Each week we highlight five things affecting the life sciences industry. Here’s the latest.
UK study suggests that borderline anemia may signal higher long-term health risks
- A large UK study found that people with hemoglobin levels just above current anemia thresholds had a higher risk of death than those with higher hemoglobin levels within the normal range, suggesting health risks may emerge before anemia is formally diagnosed.
- Per Laboratory News, reporting on research published in the Annals of Internal Medicine, the findings indicate that the relationship between hemoglobin levels and long-term health may be more complex than current diagnostic cut-offs suggest, although the study does not establish a causal relationship.
FDA oncology chief outlines AI-driven vision for cancer drug development
- Angelo de Claro, the U.S Food and Drug Administration’s new oncology chief, announced top priorities for the Oncology Center of Excellence (OCE), including: expanding artificial intelligence use in drug reviews, speeding cancer drug development and increasing U.S. clinical trial participation.
- According to Fierce Pharma, he reaffirmed support for faster approvals and key FDA oncology initiatives while emphasizing that new regulatory approaches must still meet strong scientific evidence standards.
CMS expands digital health pilot for chronic disease management
- The Centers for Medicare and Medicaid Services’ (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) pilot is expanding to cover additional chronic conditions, including heart failure, COPD, substance use disorders, and tobacco cessation, broadening access to digital health technologies for Medicare patients.
- Medtech Dive reports that more than 160 companies have joined the program, which rewards providers for using digital tools to improve patient outcomes and is aligned with a related FDA initiative designed to accelerate adoption of innovative health technologies.
FDA launches pilot to accelerate early-stage drug development
- This week, the FDA launched the Expedited Investigational New Drug pilot under Operation Trailblazer to accelerate the start of early-stage clinical trials in the U.S. by pairing drug developers with specialized research institutions and enabling rolling reviews of submissions.
- According to Biopharma Dive, the initiative is designed to make U.S. drug development more competitive with countries such as China and Australia, where faster regulatory processes have attracted a growing share of early clinical research.
Psychedelic therapies move closer to FDA approval
- The psychedelic therapeutics sector is regaining momentum, with one biotech company seeking FDA approval for its psilocybin-based depression treatment and another reporting strong late-stage results for its LSD-based therapies—positioning both companies as potential market leaders.
- According to BioSpace, growing clinical success, increased pharmaceutical investment, and supportive U.S. policy initiatives are boosting expectations that psychedelic therapies could soon secure broader regulatory approval and become new treatment options for mental health conditions.
For more insights in life sciences, check out RSM’s industry outlook.
